快橙软件

快橙软件

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

快橙软件

Learn More
Folded page of a newspaper

快橙软件

快橙软件

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

快橙软件

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

快橙软件

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

快橙软件

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

快橙软件

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

快橙软件

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

快连vnp永远连得上  黑豹加速器app下载  老虎加速器下载  佛跳墙von  快连vpn手机  快连NPA下载  极光官方vnp网页版  快连加速器官网下载安卓